Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + docetaxel + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Odense Universitetshospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the HER2-targeted monoclonal antibody trastuzumab and the chemotherapy regimen known as TEX, which includes docetaxel, oxaliplatin, and capecitabine. It was investigated in a Phase 1 dose-finding study (ECV trial) led by Odense University Hospital as a first-line treatment for patients with HER2-positive advanced gastro-esophageal adenocarcinoma, including cancers of the esophagus, cardia, and stomach. Trastuzumab works by binding to the human epidermal growth factor receptor 2 (HER2), inhibiting tumor growth signaling and inducing antibody-dependent cellular cytotoxicity (ADCC). The chemotherapy components provide synergistic cytotoxic effects: docetaxel stabilizes microtubules to prevent cell division, oxaliplatin induces DNA cross-linking to inhibit replication, and capecitabine acts as a prodrug of 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis.
- Brand names
- Herceptin + Taxotere + Eloxatin + Xeloda
- Other names
- Trastuzumab + TEX regimenHerceptin + TEX
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + docetaxel + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + docetaxel + oxaliplatin + capecitabine.